Although related bone marrow transplantation (BMT) is effective for thalassemia, less than 30% of patients have sibling donors. Here, we report unrelated BMT in nine thalassemic children using a high-resolution HLA typing technique to identify donors. HLA mismatches between donors and recipients were 0, 1 and 2 in 2, 5 and 2 cases, respectively. The results showed that white blood cells, platelets and hemoglobin all returned to normal at various time points, and blood transfusion was eliminated from 13 to 62 days after transplantation. Full engraftment was achieved in eight patients while ABO blood types were replaced with that of donors in five of the six ABO mismatched recipients. Acute skin GVHD was found in seven patients and acute liver GVHD in one. One patient with acute intestinal GVHD eventually developed chronic GVHD. One patient died of pulmonary hemorrhage in spite of having a fully functional graft. We conclude that this is the first successful application of unrelated BMT for thalassemia major in Chinese people and that the results will certainly expand donor resources and greatly enhance the survival and quality of life of thalassemic patients.
Introduction b-Thalassemia major is a life-threatening anemia caused by genetic defects in the production of the beta chain of hemoglobin (Hb). Although conventional therapy such as repeated blood transfusions as well as iron chelation to reduce iron overload has improved clinical features of the disease, severe complications such as liver and heart disorders, viral infections and dysfunction of the endocrine system remain among the major causes of poor quality of life and high mortality. Fortunately, allogeneic bone marrow transplantation (BMT) has proved to be the successful cure for over 2000 patients with thalassemia major. 1 Nevertheless, most of the allogeneic BMTs used bone marrow from HLA-identical sibling donors, which meant that over 70% of suitable patients were unable to undergo BMT. The situation is even worse in China due to not only the high incidence of the disease, being 7-10% in southern China, but also the lack of professional conventional therapy. In China, more than 90% of patients did not have access to long-term regular blood transfusion and iron chelation due to financial problems as well as the shortage of well-trained teams. In contrast to the patients in Italy who survived to their 30s using conventional therapy, patients in China usually die within their second decade from anemia or iron deposit-derived complications. According to the Pesaro classification, thalassemia major in most Chinese children of less than 3 years falls into class I, but rapidly develops to class II in children between 4 and 7 years, and deteriorates into class III stage in those over 7 years of age. Class I disease is hardly ever found in children over 10 years. Therefore, it is imperative for thalassemic children in China to undergo BMT as soon as possible for prevention of the detrimental effects of anemia or iron overload on various organs and systems, and for prolonging patients' survival time. Nevertheless, the scarcity of HLA-identical siblings in China makes related BMT impractical. Inspired by La Nasa's pioneering work, we initiated a project to investigate the significance of unrelated donor BMT in b-thalassemia. 2 The result revealed that most of the thalassemic children can be successfully cured by BMT from unrelated donors.
Materials and methods

Patients
Nine children with severe b-thalassemia were included in the present study, which ran from November 2002 to July 2004. They were eight boys and one girl, aged from 1.5 to 9 years (average: 4.3 years) and weighed 10-29 kg, with the onset of the disease at 2-6 months. They received blood transfusion (900-16500 ml) at 3-7 months. The patients were classified as class I (three cases), class II (four cases) and class III (two cases) according to Pesaro thalassemia classification criteria. Pre-transplantation check-up found mild to moderate jaundice and cardiomegaly in class II and class III patients. Serum ferritin was from 650 to 7500 mg/ml. Upon ultrasound examination, five patients had mitral regurgitation, while all nine patients showed hepatomegaly and splenomegaly. Liver biopsy in two class III patients revealed that 80% hepatocytes underwent degeneration as well as excessive iron deposit. In the portal area, there was mild fibrosis as well as massive lymphocyte infiltration (first grade fibrosis). All patients had normal liver and kidney function, and were negative for hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), herpes simplex virus and Epstein-Barr virus (EB).
Donors
All nine donors (eight males and one female, aged from 22-38 years) were registered at Tzu Chi Stem Cell Center in Taiwan. They were all positive for anti-CMV (eight for IgG and one for IgM), and one donor was positive for anti-HCV. One patient eventually received an anti-CMV (IgM) positive BMT because that was the only donor available; CMV pp65 antigen was negative in the donated bone marrow and the patient's condition did not allow us to delay. After transplantation, we monitored the CMV pp65 antigen and anti-CMV IgM of this patient every 3 months for 1 year and, fortunately, found no serum anti-CMV (IgM) or clinical CMV infection.
HLA typing HLA typing was determined by Sequence Specific Oligonucleotide Probe Hybridization (SSO PH). Among all the donor-recipient pairs, 0, 1, and 2 subtype mismatches were found in two, five and two cases, respectively, while ABO mismatches were found in six cases (Table 1) . /kg colony forming unit-granulocyte macrophages (CFU-GM) was infused. For prophylaxis of GVHD, cyclosporine (3 mg/kg) was infused at 1 day before and methotrexate (10-15 mg/m 2 day) given at 1, 3, 6 and 9 days after transplantation. Granulocyte colony-stimulating factor (G-CSF, 5-10 mg/kg) was injected daily from 5 days after the transplant for 3-4 weeks. The engraftment status was determined by polymerase chain reaction-short tandem repeat (PCR-STR). 3 
Bone marrow transplantation
Results
Unrelated BMT successfully established allogeneic bone marrow reconstruction and cured b-thalassemia major After transplantation, white blood cells (WBC) gradually recovered from zero at 1-4 days to normal at 23-100 days (average 39 days) except for two patients in whom WBC were maintained at a low level (2-3 Â 10 9 /l) for more than 4 months. Granulocytes increased to 0.5 Â 10 9 /l at 12-26 days (average 17 days). Platelets increased to 50 Â 10 9 /l at 61-142 days (average 96 days). Hb increased to 100g/l at 23-116 days (average 57 days). One patient who received ABO mismatched marrow developed obvious GVHD, poor Hb regeneration, and hemolysis that required erythrocyte transfusion for a prolonged time. At 3 weeks after transplantation, full engraftment was achieved with depletion of b-thalassemia major genes in eight patients, and ABO blood types replaced with that of donors in five of the six ABO mismatched patients. In one patient, although WBC returned to normal and PCR-STR revealed full engraftment as well as depletion of thalassemic genes, platelets unexpectedly dropped to 10-20 Â 10 9 /l. Eventually, the patient died of pulmonary hemorrhage at 27 day after transplantation. In total, seven patients (78%) had disease-free survival during the 6-25 month follow-up period (Table 2 ). Five patients with serum ferritin over 3500 mg/l after transplantation depended on phlebotomy programs and iron chelation for 10 months. At 1 year after transplantation, various kinds of infection occurred in some patients (two patients with herpes simplex virus infection, one with tympanitis, one with hepatitis B infection and one with skin fungus infection). Repeated infection in the upper respiratory tract was also found in most patients, and five of them progressed to pneumonia that was cured by antibiotics. One patient with chronic GVHD developed pulmonary infection, frequently complicated by asthma and epilepsy, three times within 1 year after transplantation. With appropriate treatment, he has now been free of asthma and epilepsy for over a year. Three patients (case 3, 7 and 9) showed mild and transient VOD and were cured by continuous infusion of prostaglandin E. 
GVHD was mild and well tolerated
Seven patients developed various grades of skin GVHD (five patients with grade 1 or 2, while two patients with grade 3) and this was reversed with methylprednisolone ( Table 2) . One patient with liver GVHD was cured by methylprednisolone and FK506. In two patients with gastrointestinal GVHD, one responded well to methylprednisolone pulse therapy and increased CsA doses, while the other with consistent watery stool (500-800 ml daily) responded only to FK506 and Budesonide. Although the diarrhea ceased after a 5-week treatment, he eventually developed chronic GVHD. Cyclosporine toxicity-related hypertensive encephalopathy was suspected in one patient who developed coma and repeated convulsions for more than 2 weeks, which was controlled by reduction of CsA doses, antihypertensive drugs and anticonvulsion therapy.
Discussion
Owing to the shortage of HLA identical sibling donors for BMT in thalassemia, the use of unrelated donors has been considered for over a decade. In 1993, Contu reported the first successful unrelated BMT for a 16-year girl, which suggested the importance of employing unrelated donors for thalassemic patients. Although the following trials to test the efficacy of unrelated BMT were generally disappointing and neglected, 4-6 two recent reports have brought thalassemic patients new hope of using unrelated donors for BMT. 2, 7 In La Nasa's investigation, among 32 patients transplanted with unrelated BMT, 22 had full engraftment and the need for blood transfusion was eliminated.
2 In Hongeng's report, all 11 children who received unrelated BMT were alive and disease-free. 7 These results highlight the possibility of using unrelated BMT to reconstitute allogeneic bone marrow and cure thalassemia. In the present study, we investigated the effect of unrelated BMT in nine Chinese children with b-thalassemia major and found that eight patients had full engraftment, while one developed recurrence of thalassemia that continued to depend on treatment with blood transfusions and iron chelation. The results are comparable to those of related BMT, indicating that unrelated BMT can be an important option for b-thalassemia major patients, 1 emphasizing the importance of further investigation on a large scale into the effect of unrelated BMT for thalassemic patients.
Patient selection and transplant protocols are the keys to improving the efficacy of unrelated BMT in thalassemic patients. We believe that the following factors may contribute to successful engraftment and high disease-free patient survival rate. First, the patients were mostly young children under 7 years, with class I or class II thalassemia and undergoing regular blood transfusion and iron chelation. Therefore, less organ dysfunction in the patients enrolled in the present study enabled them better to tolerate chemotherapy. Second, the use of high resolution HLA typing technique to select the best donor greatly reduced occurrence of GVHD. Third, the new fludarabine-based conditioning regimen reduced the effect of recipient bone marrow genesis and of immune system on the transplants, and therefore improved engraftment of the unrelated bone marrow. Fourth, more nucleated cells were transplanted to improve engraftment. Similar to the experience in Thailand, Chinese thalassemic children should undergo BMT as soon as possible because there are currently no satisfactory blood transfusion and iron chelation methods for those patients. Furthermore, as the number of volunteer donors increases, more thalassemic patients should be able to undergo unrelated BMT once diagnosis is established, reducing the possibility of iron overload-induced organ dysfunction and the risks during transplantation.
